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Background: Literature on the epidemiology of herpes zoster (HZ) in cancer patients is sparse and does not
include the elderly. The objectives of this study were to determine the incidence of HZ and related complications
in elderly cancer patients and assess risk factors associated with HZ.
Methods: Patients ≥65 years diagnosed with cancer in 1991–2007 were identified from the Surveillance, Epidemiology,
and End Results (SEER) cancer registry-Medicare linked database in this retrospective, longitudinal, open cohort study. The
observation period spanned from first cancer diagnosis until the end of data availability. A random group of non-cancer
Medicare patients served as the comparison group. Cases of HZ and related complications were ascertained from medical
claims. Incidence rates (IR) and adjusted IR ratios were reported.
Results: The study population consisted of 82,832 hematologic (HEM) and 944,777 solid cancer patients (SOLID). During
follow-up, 9.2% of HEM and 6.3% of SOLID were diagnosed with HZ. The IR of HZ was significantly higher in HEM than
SOLID (31.0 vs. 14.9 per 1,000 patient-years, p <0.01). The adjusted IR ratio vs. non-cancer elderly patients was 2.4 in HEM
and 1.2 in SOLID. The proportion of patients with complications was higher in HEM than SOLID (17.8% vs. 15.8%, p <0.01).
Age, gender, race, certain cancer therapies, and immunosuppression were HZ risk factors.
Conclusions: Elderly cancer patients run a 1.2-2.4 times higher risk of developing HZ than those without cancer.
The rates of HZ and HZ-related complications are significantly higher for hematologic than solid cancer patients.
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herpes zoster (HZ) is a vesicular rash associated with
acute pain, caused by the varicella zoster virus (VZV)
[1]. An estimated 1 million cases of HZ are reported an-
nually in the US alone [2]. The risk of HZ increases
when VZV-specific cell-mediated immunity declines, as
a result of older age and/or immunosuppressive medical
conditions and treatments [3,4].
There is sparse knowledge about the epidemiology of
HZ in cancer patients, particularly among the elderly. Esti-
mates from existing literature indicate the incidence of
HZ is 2–4 times higher in cancer patients compared to
the general population. The most recent literature on HZ
in cancer patients covers commercially-insured patients* Correspondence: Mihran.Yenikomshian@analysisgroup.com
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unless otherwise stated.diagnosed with cancer during 2001–2005 [5,6]. This study
contributes to the body of literature by analyzing patients
diagnosed with cancer during 1991–2007 and in the
Medicare population.
The objectives of this study were to estimate the inci-
dence of HZ, HZ-related pain, and HZ complications in
elderly patients with selected hematologic and solid can-
cers, and to investigate risk factors for developing HZ in
this population. Cancers were selected based on their
prevalence as well as their known elevated risk of HZ.Methods
Data source
This study utilized the Surveillance, Epidemiology, and
End Results (SEER)-Medicare database, derived from a
link between two large population-based data sources:
the SEER cancer registries data, which cover approxi-
mately 28% of the US population [7] and containentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and the Medicare enrollment and claims files, which cover
the majority of US population aged ≥65 and contain
charges and reimbursements for hospital, outpatient,
physician, and home health claims. The link between the
two databases was created by the US National Cancer In-
stitute and the Centers for Medicare and Medicaid Ser-
vices by matching individual identifiers from registries
participating in the SEER program with identifiers con-
tained in Medicare’s master enrollment file. The linked
SEER-Medicare data include the records of approximately
93% of SEER cancer patients aged ≥65 [8]. The number of
cancer registries covered by the SEER program has ex-
panded over time, including during the period covered by
our study.
The SEER program collects information about primary
cancers such as cancer site, stage, histology, and first
course of treatment for persons newly diagnosed with
cancer who reside in one of the SEER geographic areas.
The Medicare master enrollment file was used to deter-
mine which persons in the SEER data are Medicare
beneficiaries. For people who are Medicare eligible, the
SEER-Medicare data include claims for covered health-
care services, including hospital, physician, outpatient,
home health, and hospice bills.
The analyses are based on Medicare claims during 1991–
2009 of patients diagnosed with cancer during 1991–2007.
The claims data include Medicare Part D pharmacy claims
during 2007–2009. In addition, a cohort of non-cancer pa-
tients comprised of a random 5% sample of Medicare bene-
ficiaries residing in the SEER registry areas is contained in
the SEER-Medicare data and was included in our study for
comparison. The New England Institutional Review Board
approved this retrospective analysis of SEER-Medicare data
as exempt from review due to the research involving the
study of existing data (informed consent was waived).
Study design
This was a retrospective, longitudinal, open cohort study.
From the set of all Medicare-eligible patients in the SEER
registry who were diagnosed with cancer from 1991–2007,
those who were ≥65 years old at the time of cancer diagno-
sis, had ≥6 months of continuous insurance eligibility prior
to cancer diagnosis, were covered by both Part A and Part
B Medicare without Health Maintenance Organization en-
rollment, and had no evidence of cancer therapy or HZ
diagnosis prior to cancer diagnosis were included in the
main sample. Patients in the non-cancer comparison cohort
were selected based on the same criteria.
The index date for cancer patients was defined as the date
of cancer diagnosis. For the non-cancer cohort, an index
date was needed in order to facilitate comparisons with the
cancer cohorts. This index date for non-cancer patients was
randomly assigned such that, following assignment, themean and standard deviation of Medicare eligibility prior to
the index date were the same as those for cancer patients.
The observation period ran from the index date to the earl-
ier of the end of data availability (December 31, 2009) or
death.Definitions
An incident HZ case was defined as the first claim for an
HZ episode (ICD-9 codes 053.X except 053.12 and 053.13)
[9]. Both generalized and localized HZ cases were included.
HZ-associated cutaneous, visceral, neurological, and ocular
complications were identified by ICD-9 codes on claims
within 90 days after any HZ claim in cases for which there
was no claim for the complication prior to the date of first
HZ diagnosis [2,10,11]. Given the time period and availabil-
ity of data, the following criteria for HZ-related pain applied
to the vast majority of patients: (i) two or more visits with
an HZ diagnosis more than 28 days apart; or (ii) a diagnosis
for HZ with other nervous system complications (ICD-9-
CM 053.1x) or a diagnosis for neuralgia (ICD-9-CM 729.2)
within 180 days of a visit for HZ. With the availability of
Medicare Part D data beginning in 2007, a new prescription
for a medication used to treat HZ-related pain was also re-
quired within 60 days of the HZ visits in the first criterion.
A similar definition was adopted by Klompas, et al. to ad-
dress the under-coding of post-herpetic neuralgia [12]. This
definition accounts for the possibility that pain is underre-
ported in the claims data by allowing for HZ-related pain
without a pain claim (see Additional file 1: Table S1 for
codes used to identify pain and pain interventions). We in-
clude in our estimates of the percentage of patients in-
stances in which claims for HZ-related complications (see
Additional file 1: Table S2 for the codes used to identify
HZ-related complications) occur on the same claim as the
initial HZ diagnosis since this is a relatively frequent occur-
rence in the data. In these instances, we cannot be certain
that what we are observing are incident complications.
Hence, the estimates of the percentage of patients develop-
ing each complication can be characterized as the preva-
lence of the complication within the 90-day period
following HZ diagnosis.Statistical analysis
Demographic characteristics, observation time pre- and
post-index date, and the Charlson Comorbidity Index
(see Additional file 1: Table S3 for the description of the
Charlson Comorbidity Index) [13-15] were reported.
Cancer patients were stratified by cancer site and into
cohorts based on cancer type (hematologic and solid).
Frequencies and proportions (means and standard devia-
tions) were reported for categorical variables (continuous
variables). Differences between any cancer and non-cancer,
hematologic and non-cancer, and solid and non-cancer
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egorical and continuous variables, respectively.
The HZ incidence rate (IR) was estimated as the number
of patients with incident HZ divided by person-years (PY) of
observation censored at the earlier of first event or death.
Confidence intervals (CI) were estimated using the exact
Poisson confidence limit. Results were stratified by cancer
site. A z-test was used to assess the difference between IRs
of HZ for hematologic vs. solid cancers.
Adjusted incidence rate ratios (IRR) of HZ in cancer
vs. non-cancer patients and 95% CIs were estimated by
Poisson regressions using the covariates age at diagno-
sis, gender, HIV-positive, diabetic, race, and immuno-
compromising conditions/medications (e.g., rheumatoid
arthritis, lupus erythematosus, medications inhibiting
tumor necrosis factor – see Additional file 1: Table S3
for description of immunocompromising conditions/
medications) to assess the incremental risk of HZ for
cancer vs. non-cancer patients. Separate regressions
were run on the samples of hematologic and solid can-
cer patients. Risk factors for developing HZ were
assessed with IRRs estimated from Poisson regressions
with the same set of covariates listed above as well as re-
ceipt of certain cancer therapies (hematologic cancer
patients: autologous and allogeneic stem cell trans-
plants; solid cancer patients: radiotherapy) and cancer
stage at diagnosis (solid cancer patients only). Covari-
ates whose estimated IRRs differed significantly from 1.0
were deemed to be risk factors for HZ. The proportions of
patients with HZ at different time points during follow-up
were also calculated. Receipt of chemotherapy, which was
expected to be highly correlated with receipt of antiviral
prophylaxis, could not be assessed as an independent HZ
risk factor due to the lack of available pharmacy claims data
prior to 2007.
Frequencies of events, observation time, proportions of
HZ patients, and IRs for HZ-related complications were
reported separately for the hematologic and solid cohorts.
Events, observation time, and proportion of patients were
based on complications diagnosed within 90 days of HZ
diagnosis, and should thus be interpreted as the 90 day
prevalence of complications. The IRs for HZ-related com-
plications were calculated by Poisson regression with a log
link. Patients with complications diagnosed on the same
day as HZ are excluded from the regression due to lack of
follow-up time. Reported estimates of 95% CIs for the IRs
were estimated using the exact Poisson confidence limit.
Frequencies of events and proportions of patients with
HZ-related pain were reported by cancer site. Z-tests were
used to assess the difference between the proportions of
hematologic and solid cancer patients who developed HZ-
related complications and pain.
All data analyses were performed using SAS release 9.2
or newer (SAS Institute, Inc., Cary, NC).Results
Sample characteristics
From an initial sample of 2,110,735 cancer and 676,712
non-cancer patients, the final sample included 82,832
hematologic, 944,777 solid, and 246,308 non-cancer pa-
tients (see Figure 1). Patient baseline characteristics are
presented in Table 1. Significant differences existed be-
tween cancer and non-cancer patients in all characteris-
tics considered. Due to the large sample size, not all
statistically significant differences were meaningful. The
average age at the index date was approximately 75–78
years across the cohorts. Compared with non-cancer pa-
tients, hematologic and solid cancer patients were
slightly older on average (mean ages 77.5 and 76.1 vs.
74.7 years, p-values <0.0001). Most (62.7%) non-cancer
patients were female, while hematologic cancer patients
were roughly evenly divided across genders (51.0% fe-
male) and solid cancer patients tended to be male
(55.1%). Most (84-89%) patients were White in race.
Compared with non-cancer patients, larger proportions
of hematologic and solid cancer patients were White
(89.3% and 86.4%, respectively, vs. 84.1%), while smaller
proportions were Asian/Pacific Islanders (2.2-2.3% vs.
3.2%) and North American Native/Alaska Native (0.2%
vs. 0.4%). A smaller proportion of hematologic cancer
patients were Black (4.7%) compared with solid cancer
(7.9%) and non-cancer (7.6%) patients. Average follow-
up times for hematologic and solid cancer patients were
37.8 and 52.1 months, respectively, and were signifi-
cantly shorter compared to non-cancer patients (mean
85.3 months, p-values <0.0001).
Incidence rates of herpes zoster
Results on the IR of HZ are presented in Table 2. Across
the cancer types considered, the IR of HZ was lowest for
patients with prostate cancer and highest for patients
with Hodgkin’s Lymphoma (12.3 and 47.8 per 1,000 PY,
respectively). The IR of HZ was significantly higher in
the hematologic vs. solid cancer cohort (31.0 vs. 14.9 per
1,000 PY, p < 0.01). Both hematologic and solid cancer
patients were more likely to develop HZ compared to
non-cancer patients (adjusted IRRs of 2.36 and 1.19, p-
values < 0.001).
The proportions of patients developing HZ by time
since index date are plotted in Figure 2 (cancer patients in
this analysis were required to have survived for at least
2 years after cancer diagnosis). Approximately 3.75% and
1.50% of patients in the hematologic and solid cancer co-
horts developed HZ within 1 year of cancer diagnosis,
compared with 1.10% of non-cancer patients. The propor-
tions of hematologic and solid cancer patients who devel-
oped HZ within 2 years of cancer diagnosis were 6.6% and
3.0%, respectively. Overall, 9.2% of hematologic and 6.3%
of solid cancer patients were diagnosed with HZ during
Note: 
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Figure 1 Study population disposition. The flow chart depicts how the selection criteria affect the number of patients remaining in the study
sample. Each box represents the number of patients remaining in the sample at each step. From an initial sample of 2,110,735 cancer and
676,712 non-cancer patients, the final sample included 82,832 hematologic, 944,777 solid, and 246,308 non-cancer patients.
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dian time of HZ onset following cancer diagnosis was
34.0 months (24.8 and 35.4 months for hematologic and
solid tumor patients, respectively).
herpes zoster risk factors
Results from the analysis of risk factor for HZ are pre-
sented in Table 3. Age, gender, race, and immunocompro-
mising conditions and/or medications were statistically
significant risk factors for HZ. Conditional on cancer sta-
tus, estimates from the sample that included hematologic
cancer patients indicate that patients 75 to 85 years old
ran a higher risk of developing HZ compared with patients
≥85 years (IRR = 1.12, p < 0.001). Males were at lower risk
of developing HZ than females (IRR = 0.83, p < 0.001).
Black patients were less likely to develop HZ than white
patients (IRR = 0.64, p < 0.001). Patients who had immu-
nocompromising conditions other than HIV ran a higher
risk of developing HZ (IRR = 1.25, p < 0.001). Finally, re-
ceipt of autologous or allogeneic stem cell transplants was
associated with a higher risk of developing HZ (IRRs of
2.07, p < 0.001; and 1.92, p = 0.024, respectively). Results
from the sample that included solid cancer patients were
largely similar. Radiotherapy recipients ran a slightly lower
risk of developing HZ compared to solid cancer patients
who did not receive radiotherapy (IRR = 0.94, p < 0.001)
while patients with stage III/IV cancer at diagnosis ran a
higher risk of developing HZ (IRR = 1.20, p < 0.001).herpes zoster-related complications and pain
Results on the incidence of HZ-related complications in
hematologic and solid cancer patients are presented in
Table 4. Among hematologic cancer patients, the range of
IRs across the different types of complications considered
was wide (0.0 for deafness, other neurological complications,
and panopthalmitis to 132.5 for postherpetic polyneurop-
athy and postherpetic trigeminal neuralgia). 17.8% of
hematologic cancer patients developed some type of compli-
cation (IR = 530.0 per 1,000 PY). Ophthalmic complications
were the most prevalent (11.3% of patients; IR = 247.3 per
1,000 PY) compared with the other types of complications
considered aside from HZ-related pain. Similar proportions
of hematologic and solid cancer patients developed HZ-
related complications across the major categories of compli-
cations considered, although a significantly larger share of
hematologic cancer patients developed complications
(17.8% vs. 15.8% of patients, p < 0.01).
Results on the incidence of HZ-related pain are presented
in Table 5. The proportions of hematologic and solid cancer
patients who developed HZ-related pain were 47.7% and
41.0%, respectively. Significantly higher proportions of
hematologic cancer patients developed HZ-related pain
compared to solid cancer patients (p-values < 0.01).
Discussion
This study of elderly patients was undertaken to describe
the characteristics of patients with and without cancer,











Age at index date, mean ± SD3 77.5 ± 7.3 76.1 ± 6.9 74.7 ± 7.2 <0.0001 <0.0001
Gender, n (%)
Male 40,516 (49.0%) 516,011 (55.1%) 91,940 (37.3%) <0.0001 <0.0001
Female 42,232 (51.0%) 419,916 (44.9%) 154,368 (62.7%) <0.0001 <0.0001
Race, n (%)
White 73,895 (89.3%) 808,178 (86.4%) 207,161 (84.1%) <0.0001 <0.0001
Black 3,923 (4.7%) 74,168 (7.9%) 18,760 (7.6%) <0.0001 <0.0001
Asian/Pacific Islander 1,800 (2.2%) 21,116 (2.3%) 7,811 (3.2%) <0.0001 <0.0001
Hispanic 1,203 (1.5%) 12,237 (1.3%) 5,896 (2.4%) <0.0001 <0.0001
North American Native/Alaska Native 155 (0.2%) 1,952 (0.2%) 901 (0.4%) <0.0001 <0.0001
Other 1,489 (1.8%) 15,674 (1.7%) 5,013 (2.0%) <0.0001 <0.0001
Months before the index date, mean ± SD3 110.9 ± 64.8 101.4 ± 62.4 85.6 ± 47.6 <0.0001 <0.0001
Months after the index date, mean ± SD3 37.8 ± 41.3 52.1 ± 48.8 85.3 ± 62.6 <0.0001 <0.0001
Charlson Comorbidity Index, mean ± SD3 0.7 ± 1.1 0.7 ± 1.1 0.5 ± 0.9 <0.0001 <0.0001
Notes:
1Hematologic cancers include chronic lymphocytic leukemia, acute lymphocytic or acute myeloid leukemia, other leukemia, Hodgkin’s lymphoma, and
non-Hodgkin’s lymphoma.
2Solid cancers include bladder cancer, breast cancer, colorectal cancer, head and neck cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, and soft
tissue sarcoma.
3SD = standard deviation








non-cancer patients (95% CI)1
P-value
All Cancers 1,027,609 66,222 4,161,133 15.9 (15.8-16.0) 1.27 (1.25-1.29) <0.001
Hematologic Cancers2 82,832 7,574 244,187 31.0 (30.3-31.7) 2.36 (2.30-2.42) <0.001
Chronic Lymphocytic Leukemia 14,035 1,754 56,875 30.8 (29.4-32.3) 2.37 (2.26-2.49) <0.001
Acute Lymphocytic or Acute
Myeloid Leukemia
9,614 257 7,125 35.9 (31.8-40.6) 2.75 (2.43-3.11) <0.001
Other Leukemia 7,803 391 15,685 24.9 (22.5-27.5) 1.90 (1.72-2.11) <0.001
Hodgkin’s Lymphoma 2,147 283 5,923 47.8 (42.5-53.7) 3.56 (3.17-4.01) <0.001
Non-Hodgkin’s Lymphoma 49,233 4,891 158,773 30.7 (29.9-31.6) 2.31 (2.24-2.39) <0.001
Solid Cancers2 944,777 58,670 3,921,307 14.9 (14.8-15.1) 1.19 (1.17-1.21) <0.001
Bladder Cancer 67,811 4,140 293,432 14.1 (13.7-14.5) 1.11 (1.08-1.16) <0.001
Breast Cancer 173,635 15,819 963,395 16.4 (16.2-16.7) 1.17 (1.14-1.19) <0.001
Colorectal Cancer 129,761 7,354 504,238 14.6 (14.2-14.9) 1.11 (1.08-1.14) <0.001
Head and Neck Cancer 48,876 2,530 173,559 14.6 (14.0-15.2) 1.14 (1.09-1.19) <0.001
Lung Cancer 200,734 6,376 287,656 22.1 (21.6-22.7) 1.61 (1.56-1.66) <0.001
Melanoma 52,026 3,961 268,256 14.8 (14.3-15.2) 1.15 (1.11-1.19) <0.001
Ovarian Cancer 18,715 844 48,762 17.3 (16.2-18.5) 1.21 (1.13-1.30) <0.001
Prostate Cancer 247,939 17,371 1,406,361 12.3 (12.2-12.5) 1.12 (1.09-1.15) <0.001
Soft Tissue Sarcoma 5,280 275 18,206 15.1 (13.4-16.9) 1.16 (1.03-1.31) 0.016
Notes:
1IR = incidence rate; IRR = IR ratio; CI = confidence interval.
2P-value of difference in IR of HZ for hematologic vs. solid cancer <0.01.
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Figure 2 Proportions of patients developing herpes zoster after cancer diagnosis. The proportions of patients developing HZ by time since
index date are plotted. Cancer patients in this analysis were required to have survived for at least 2 years after cancer diagnosis. The proportion
of patients being diagnosed with HZ was plotted for the overall, hematologic, solid tumor, and non-cancer cohorts. Dashed lines indicate the
percentage of each cohort with HZ at 1 year since the index date. Approximately 3.75% and 1.50% of patients in the hematologic and solid
cancer cohorts developed HZ within 1 year of cancer diagnosis, compared with 1.10% of non-cancer patients. The proportions of hematologic
and solid cancer patients who developed HZ within 2 years of cancer diagnosis were 6.6% and 3.0%, respectively.
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onset of HZ, HZ-related pain, and HZ complications in
elderly cancer patients, and assess risk factors for devel-
oping HZ. The SEER-Medicare database facilitated the
use of large samples of cancer patients, as well as a sam-
ple of non-cancer patients for comparison purposes.
This study found significantly higher HZ incidence
rates in cancer vs. non-cancer patients. Specifically, eld-
erly cancer patients ran a 1.2-2.4 times higher risk of de-
veloping HZ than those without cancer. Incidence rates
of HZ were lowest among patients with prostate cancer
and highest among patients with Hodgkin’s Lymphoma.
Hematologic cancer patients tended to have the highest
HZ incidence rates and develop HZ more quickly fol-
lowing cancer diagnosis. These findings are consistent
with the previous findings of Habel, et al. and Rustho-
ven, et al. [6,16]. In particular, the HZ incidence rates
reported by Habel, et al. in a study of a commercially-
insured cancer population (31 and 12 per 1,000 PY for
hematologic and solid cancer patients, respectively) are
very similar to those found here [6]. In addition, the
proportions of hematologic and solid cancer patients
developing HZ within 2 years of cancer diagnosis found
in this study (6.6% and 3.0%, respectively) are compar-
able to those reported by Habel et al. (6% and 2%, re-
spectively). Hematologic cancer patients also developedHZ-related complications and pain more frequently than
solid cancer patients. The proportion of hematologic can-
cer patients with HZ developing neurologic complications
(4.5%) was comparable to, and developing cutaneous and
ophthalmic complications differed from, those reported
elsewhere in the literature [6,17]. In particular, the propor-
tion of hematologic cancer patients with HZ that devel-
oped ophthalmic complications found in this study
(11.3%) is substantially larger than that reported by Habel
et al. (3.6%), as well as that reported by Yawn et al. in a
study of HZ in non-cancer patients in Olmsted County,
MN based on medical record review (4.1%) [6,17].
Risk factors for developing HZ included age, gender,
race, immunosuppressive conditions, and certain cancer
therapies. Males and black patients (relative to white pa-
tients) had a lower risk for developing HZ, consistent
with data reported by Opstelten et al. [18] (gender risk
factors) and Schmader et al. [19,20] (race risk factors).
Hematologic or solid cancer patients with immunocom-
promising conditions ran a higher risk of developing HZ, as
did hematologic cancer patients who received stem cell
transplants (despite the routine use of HZ prophylaxis post-
transplant). Additionally, solid cancer patients with a stage
III/IV cancer were at a higher risk for developing HZ.
Cancer patients aged 75 to 85 years old had a higher risk of
developing HZ than patients 85 years and older. This
Table 3 Risk factors for herpes zoster
Variable Hematologic cancers Solid cancers
(n = 82,832) (n = 944,777)
Incidence rate
ratio
95% CI1 P-value Incidence rate
ratio
95% CI1 P-value
Age at diagnosis (ref = 85+ years old)
65 to 75 years old 1.05 (1.00 - 1.10) 0.067 0.97 (0.94 - 1.00) 0.025
75 to 85 years old 1.12 (1.07 - 1.18) <0.001 1.04 (1.01 - 1.07) 0.014
Male (ref = female) 0.83 (0.81 - 0.85) <0.001 0.80 (0.78 - 0.81) <0.001
Race (ref = white)
Black 0.64 (0.50 - 0.81) <0.001 0.60 (0.51 - 0.70) <0.001
Asian/Pacific Islander 1.25 (0.98 - 1.60) 0.074 1.28 (1.08 - 1.51) 0.003
North American Native/Alaska Native 1.06 (0.77 - 1.46) 0.730 0.92 (0.74 - 1.16) 0.488
Other or Unknown 1.11 (0.87 - 1.43) 0.398 1.16 (0.98 - 1.37) 0.089
Diabetes 1.02 (0.98 - 1.07) 0.344 0.99 (0.96 - 1.01) 0.225
HIV-positive (ref = HIV-negative) 0.82 (0.41 - 1.65) 0.587 1.16 (0.78 - 1.72) 0.451
Other immunocompromising conditions and/or medications2 1.25 (1.20 - 1.30) <0.001 1.26 (1.23 - 1.28) <0.001
Cancer patient 2.35 (2.29 - 2.42) <0.001 1.18 (1.15 - 1.21) <0.001
Receipt of autologous stem cell transplant 2.07 (1.49 - 2.89) <0.001 N/A
Receipt of allogeneic stem cell transplant 1.92 (1.09 - 3.38) 0.024
Receipt of radiotherapy N/A 0.94 (0.93 - 0.96) <0.001
Stage I/II at diagnosis 1.01 (0.99 - 1.03) 0.269
Stage III/IV at diagnosis 1.20 (1.16 - 1.23) <0.001
Notes:
1CI = confidence interval.
2See Additional file 1: Table S3 for the definition of other immunocompromising conditions and/or medications.
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proaches (e.g., more aggressive chemotherapies, inducing
greater immune suppression) used to treat elderly cancer
patients aged 75 to 85 for cancer and other illnesses com-
pared with approaches used to treat elderly cancer patients
85 years and older. These different treatment approaches
may lead to different HZ risks. Habel, et al. reports a similar
decreased risk of HZ for cancer patients 80 years and older
compared to those younger than 80 years, but only among
patients with hematologic cancers [6].
There is a wide range of estimates of post-herpetic neural-
gia incidence ranging from <1% to 70% previously reported
in the literature, with this study reporting proportions of pa-
tients with HZ-related pain (41.0% and 47.7% for solid and
hematologic cancer patients, respectively) on the higher end
[21-23]. This higher estimate may be a result of a possible
lack of specificity of the claims data definition employed on
the cancer population. Cancer patients may have other pain-
ful conditions associated with their oncological therapy that
may be getting attributed to HZ-related pain.
This study has several notable limitations. As with all
claims database analyses, ICD-9 codes were used to
identify diagnoses; these codes may not reflect con-
firmed clinical diagnoses and lack information to assessseverity of illness. Medical services obtained outside of a
patient’s plan are not captured in claims data, so HZ
incidence in this study may be underestimated. The
analysis of HZ-related pain may not reflect the true inci-
dence of HZ-related pain in the studied populations.
Specifically, the definition may cause our study to over-
state the incidence of HZ-related pain among cancer pa-
tients compared with non-cancer patients by classifying
general cancer-related pain as HZ-related pain, particu-
larly since pain may be more likely to be diagnosed in
cancer patients (who likely receive regular evaluations
and treatment) compared with non-cancer patients. No
validation of codes and algorithms for identifying HZ
and its complications was performed. However, a study
that performed validation with comparison to electronic
medical records found high positive predictive value
(PPV) for identifying HZ and its complications (78%-
93%) [12]. The SEER-Medicare data extract used in this
study did not include patients with multiple myeloma.
Receipt of chemotherapy was not analyzed as an HZ
risk factor due to the lack of available pharmacy claims
data prior to 2007. Finally, some of the steroids defined
as immunosuppressive treatments could be part of a
cancer treatment protocol.
Table 4 Incidence of HZ complications in hematologic and solid cancer patients



















Any Complication3,4 1,348 1,421 17.8 530.0 (493.5-569.3) 9,253 11,483 15.8 398.3 (386.9-410.0)
Cutaneous Complications 291 1,652 3.8 122.8 (107.1-141.0) 1,462 13,296 2.5 73.6 (69.1-78.3)
Cellulitis 289 1,653 3.8 122.2 (106.5-140.3) 1,456 13,297 2.5 73.2 (68.7-77.9)
Zoster gangrenosum <11 1,776 <0.2 0.6 (0.1-4.0) <11 13,973 <0.1 0.4 (0.1-0.9)
Visceral Complications <11 1,775 <0.2 3.4 (1.5-7.5) <11 13,974 <0.1 0.2 (0.1-0.7)
Pneumonitis <11 1,775 <0.2 3.4 (1.5-7.5) <11 13,974 <0.1 0.2 (0.1-0.7)
Neurological Complications 339 1,716 4.5 174.8 (156.1-195.7) 1,860 13,633 3.2 121.7 (116.0-127.7)
Aseptic meningitis <11 1,775 <0.2 4.5 (2.3-9.0) 30 13,969 0.1 1.5 (1.0-2.3)
Cranial nerve palsies 42 1,766 0.6 18.1 (12.8-25.6) 223 13,918 0.4 11.9 (10.2-13.8)
Deafness <11 1,777 <0.2 0.0 (0.0-0.0) <11 13,974 <0.1 0.1 (0.0-0.6)
Diaphragmatic paralysis <11 1,776 <0.2 2.8 (1.2-6.8) 52 13,964 0.1 3.2 (2.3-4.2)
Encephalitis 26 1,772 0.3 13.0 (8.6-19.5) 106 13,953 0.2 6.5 (5.3-8.0)
Motor neuropathy <11 1,776 <0.2 0.6 (0.1-4.0) 17 13,971 0.0 1.2 (0.8-2.0)
Postherpetic polyneuropathy and postherpetic trigeminal neuralgia 252 1,735 3.3 132.5 (116.5-150.8) 1,393 13,739 2.4 93.7 (88.8-99.0)
Sensory loss <11 1,775 <0.2 4.5 (2.3-9.0) 66 13,959 0.1 4.7 (3.7-6.0)
Transverse myelitis <11 1,776 <0.2 1.1 (0.3-4.5) 16 13,972 0.0 1.1 (0.7-1.9)
Other complications <11 1,777 <0.2 0.0 (0.0-0.0) <11 13,975 <0.1 0.0 (0.0-0.0)
Ophthalmic Complications 853 1,565 11.3 247.3 (223.8-273.2) 6,689 12,276 11.4 218.5 (210.4-226.9)
Dermatitis of eyelid 337 1,700 4.4 94.1 (80.6-109.9) 2,626 13,363 4.5 79.8 (75.1-84.7)
Iridocyclitis/Uveitis/Chorioretinitis/Retinitis 84 1,759 1.1 31.3 (24.0-40.7) 624 13,836 1.1 31.2 (28.4-34.3)
Keratoconjunctivitis 289 1,711 3.8 75.4 (63.4-89.6) 2,058 13,499 3.5 60.3 (56.3-64.6)
Keratitis 95 1,752 1.3 49.1 (39.7-60.6) 641 13,786 1.1 39.0 (35.8-42.4)
Mydriasis <11 1,777 <0.2 0.6 (0.1-4.0) <11 13,975 <0.1 0.1 (0.0-0.5)
Panopthalmitis <11 1,777 <0.2 0.0 (0.0-0.0) <11 13,975 <0.1 0.0 (0.0-0.0)
Ptosis 16 1,771 0.2 9.0 (5.5-14.7) 184 13,928 0.3 12.3 (10.6-14.3)
Scleritis 111 1,735 1.5 54.2 (44.3-66.3) 758 13,632 1.3 43.4 (40.1-47.1)
Visual impairment 33 1,768 0.4 15.8 (10.9-22.9) 204 13,915 0.3 12.2 (10.5-14.2)
Other complications 209 1,731 2.8 56.6 (46.4-69.0) 1,687 13,592 2.9 47.3 (43.8-51.1)
Notes:
1First events, person-years of observation, and % with event based on complications diagnosed within 90 days of HZ diagnosis and should thus be interpreted as the 90-day prevalence of complications. Incidence
rates are estimated by Poisson regression with a log link. Patients with complications diagnosed on the same day as HZ are excluded from the regression due to lack of follow-up time. Thus, dividing the number of
first events by the person-years of observation will not match the incidence rate estimates.
2CI = confidence interval.
3The p-value of the difference in % with any complication for hematologic vs. solid cancer was <0.01.














Table 5 Incidence of herpes zoster-related pain
Outcome Measure First events Population1 % with herpes zoster-related pain
All Cancer 27,664 66,222 41.8
Hematologic Cancers2 3,611 7,574 47.7
Chronic Lymphocytic Leukemia 914 1,754 52.1
Acute Lymphocytic or Acute Myeloid Leukemia 79 257 30.7
Other Leukemia 161 391 41.2
Hodgkin’s Lymphoma 133 283 47.0
Non-Hodgkin’s Lymphoma 2,324 4,891 47.5
Solid Cancers2 24,070 58,670 41.0
Bladder Cancer 1,716 4,140 41.4
Breast Cancer 6,822 15,819 43.1
Colorectal Cancer 3,010 7,354 40.9
Head and Neck Cancer 1,030 2,530 40.7
Lung Cancer 2,495 6,376 39.1
Melanoma 1,666 3,961 42.1
Ovarian Cancer 343 844 40.6
Prostate Cancer 6,847 17,371 39.4
Soft Tissue Sarcoma 141 275 51.3
Notes:
1Patients were observed following the incident diagnosis of herpes zoster.
2P-values of differences in % of patients with herpes zoster-related pain for hematologic vs. solid cancer <0.01.
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The results of this study indicate that elderly cancer pa-
tients face an increased risk of HZ compared to non-
cancer patients. Elderly patients with hematologic cancers
are particularly vulnerable to HZ and related complica-
tions and pain. Gender, race, and certain immunocompro-
mising conditions and certain cancer therapies are risk
factors for HZ. Further research on HZ in cancer patients
is needed within the context of non-Medicare populations
as well as patients with multiple myeloma.
Ethics statement
The New England Institutional Review Board approved
this retrospective analysis of Surveillance Epidemiology
and End Results Medicare data for Medicare beneficiar-
ies. This research was determined to be exempt from
NEIRB review as it involved study of existing data. In-
formed consent was waived since the study does not in-
volve intervention or interactions with individuals, only
registry and claims data are used. The SEER-Medicare
contact at the National Cancer Institute reviewed the
manuscript and verified that there are no confidentially
issues with the presented data.
Additional file
Additional file 1: Table S1. Codes to Identify Pain and Pain
Interventions. Table S2. ICD-9 Codes to Identify HZ Complications.
Table S3. Additional Variable Descriptions.Abbreviations
HZ: herpes zoster; VZV: Varicella Zoster Virus; SEER: Surveillance,
Epidemiology, and End Results; IR: Incidence rate; PY: Person-years;
CI: Confidence intervals; IRR: Incidence rate ratios.
Competing interests
Research support was provided to Analysis Group, Inc. by GlaxoSmithKline
Biologicals SA, Belgium. M. Yenikomshian, P. Karner, A. Trahey, and M. Duh
were employees of Analysis Group, Inc. at the time the study was conducted
A. Guignard and F. Haguinet are employees of the GlaxoSmithKline group of
companies, A. Guignard receives stock equity as part of her compensation. A.
Skarin and A. LaCasce are employees of the Dana-Farber Cancer Institute and
have received consultation fees from GlaxoSmithKline Vaccines for this study.
Authors’ contributions
AG conceived of the study. APG and FH designed the study. MAY, AT, PK,
and MSD coordinated the study, prepared the data, and performed the
statistical analysis. AL and AS provided clinical input on the study design and
interpretation of results. All authors interpreted the findings. MAY and PK
wrote the manuscript drafts. All authors critically reviewed different
manuscript drafts and read and approved the manuscript.
Acknowledgements
Publication management and editorial support was provided by Jarno Jansen
(Keyrus biopharma on behalf of GlaxoSmithKline Vaccines). This study used the
linked SEER-Medicare database. The interpretation and reporting of these data
are the sole responsibility of the authors. The authors acknowledge the efforts
of the Applied Research Program, NCI; the Office of Research, Development and
Information, CMS; Information Management Services (IMS), Inc.; and the
Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in
the creation of the SEER-Medicare database.
Author details
1Analysis Group, Inc., 111 Huntington Ave., Tenth Floor, Boston, MA 02199,
USA. 2GlaxoSmithKline Vaccines, Wavre, Belgium. 3Dana-Farber Cancer
Institute, Boston, MA, USA.
Yenikomshian et al. BMC Infectious Diseases  (2015) 15:106 Page 10 of 10Received: 20 May 2014 Accepted: 6 February 2015
References
1. Arvin AM, Gershon A. Varicella-Zoster Virus – Virology and Clinical Management.
1st ed. UK: Cambridge University Press; 2000.
2. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization
Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention
of herpes zoster: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR Recomm Rep. 2008;6:1–30.
3. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al.
Recommendations for the management of herpes zoster. Clin Infect Dis.
2007;44:S1–26.
4. Cohen J. Herpes Zoster. N Engl J Med. 2013;369:255–63.
5. Habel LA, Ray GT, Horberg M, Yawn B, Castillo A, Li Y, et al. The
epidemiology of herpes zoster in patients with invasive cancer. J Clin Oncol.
2009;27:9562.
6. Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al.
The epidemiology of herpes zoster in patients with newly diagnosed
cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:82–90.
7. National Cancer Institute (NCI): SEER. [http://seer.cancer.gov/about/overview.
html] Accessed Nov. 7, 2013.
8. NCI: SEER-Medicare: How the SEER & Medicare Data are Linked. [http://
healthservices.cancer.gov/seermedicare/overview/linked.html]
Accessed Nov. 7, 2013.
9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of
herpes zoster in a United States administrative database. J Gen Intern Med.
2005;20(8):748–53.
10. Volpi A. Severe complications of herpes zoster. Herpes. 2007;14:35–9.
11. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the
United States. J Am Osteopath Assoc. 2007;107:S2–7.
12. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes Zoster and
Postherpetic Neuralgia Surveillance using structured electronic data.
Mayo Clin Proc. 2011;86:1146–53.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373–83.
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol.
1993;46(10):1075–9.
16. Rusthoven JJ, Ahlgren P, Elhakim T, Pinfold P, Reid J, Stewart L, et al.
Varicella-zoster infection in adult cancer patients: a population study.
Arch Intern Med. 1988;148:1561–6.
17. Yawn BP, Wollan P, St. Sauver J. Comparing shingles incidence and
complication rates from medical record review and administrative database
estimates: How close are they? Am J Epidemiol. 2011;174:1054–61.
18. Opstelten W, Van Essen GA, Schellevis F, Verheij TJ, Moons K. Gender as an
independent risk factor for herpes zoster: a population-based prospective.
Ann Epidemiol. 2006;16:692–5.
19. Schmader K, George LK, Burchett BM, Pieper CF. Racial differences in the
occurrence of herpes zoster. J Infect Dis. 1995;171:701–4.
20. Schmader K, George LK, Burchett BM, Hamilton JD, Pieper CF. Race and
stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc.
1998;46:973–7.
21. Gnann Jr JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med.
2002;347:340–6.
22. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen
GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators
using a general practice research database. Fam Pract. 2002;19:471–5.
23. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A
population-based study of the incidence and complication rates of herpes
zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
